You just read:

Tuberous Sclerosis Alliance salutes FDA approval of Afinitor® DISPERZ (everolimus) as the first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures

News provided by

Tuberous Sclerosis Alliance

Apr 10, 2018, 21:43 ET